Format

Send to

Choose Destination
J Dermatolog Treat. 2019 Feb 3:1-5. doi: 10.1080/09546634.2018.1529385. [Epub ahead of print]

Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris.

Author information

1
a Centre de Pharmacologie Clinique Appliquée à la Dermatologie , Nice , France.
2
b LEO Pharma A/S , Ballerup , Denmark.
3
c Service de Dermatologie , University Hospital of Nice , Nice , France.

Abstract

BACKGROUND:

It is important to determine the vasoconstrictor potencies of topical corticosteroids used to treat psoriasis to ensure appropriate clinical use.

OBJECTIVE:

To compare the vasoconstrictive potencies of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) (Cal/BD) cutaneous foam with other topical corticosteroids.

METHODS:

In this Phase I, single-center, healthy volunteer study, Cal/BD foam, clobetasol propionate 0.05% cream (CP; very potent), BD 0.05% ointment (potent), mometasone furoate 0.1% cream (MF; potent), hydrocortisone-17-butyrate 0.1% ointment (HB; moderately potent), and foam vehicle were applied, then removed after 16 h. Skin blanching was visually assessed 2 h later (scale of 0-4).

RESULTS:

Thirty-six volunteers were randomized. Skin blanching with Cal/BD foam (median [range], 2.00 [0.75-3.00]) was significantly lower than CP cream (3.00 [1.75-4.00]; p < .001), was not significantly different from BD ointment (1.75 [0.75-3.00]; p = .30) and MF cream (2.00 [1.00-3.75]; p = .22), and was significantly greater than HB ointment (1.25 [0.50-3.00]; p < .001) and vehicle (0 [0-0.50]; p < .001). There were no local tolerability reactions or adverse events.

CONCLUSIONS:

The corticosteroid potency of Cal/BD foam was not significantly different from BD ointment and MF cream, significantly stronger than HB ointment, but weaker than CP cream in healthy volunteers.

KEYWORDS:

Aerosol foam; betamethasone dipropionate; calcipotriol; corticosteroid; psoriasis vulgaris; topical

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center